State of the Art

Project CleanAir

Air decontamination in hospitals is currently accomplished by using passive filters such as HEPA, which have the disadvantage that they only can filter particles down to a size of approximately 500nm (COVID-19 virus ≤120nm). Additionally, the pollutants separated from the air are only collected in the filter and not inactivated. As a result, there is not only the risk that a proportion of the pollutants cannot be collected at all, but the filter itself may act as nutrient for further pathogen growth and clusters of alive viruses which may be released into the room air again.

Picture: CleanAir system development for medical facilities; system layout as ceiling panel

Uniqueness of CleanAir

Villinger´s air disinfection technology is called LEA™ and is based on an electrokinetic system with large area electrode arrays which are able to inactivate Airborne pathogens and particles down to the size of atoms without producing any harrmful byproducts like Ozone or NOx.
Cleanair systems with LEA™ air disinfection already got tested in the U.S. at an independent FDA-certified testing laboratory which confirms that LEA™ air disinfection technology provides an unrivaled 99.99992% reduction rate of airborne bioaerosols such as viruses, bacteria and other pathogens from the without any measurable harmful byproducts.

The installation of CleanAir will set new hygiene and safety standards in medical facilities and other enclosed enviroments.

Amazing Test Results

The graph shows the linear trend line of the Cleanair System with LEA™ system as an estimate of the theoretically achievable reduction in the test time allotted for such tests, above the detection limit of the test procedure.
Based on this extrapolation, the expected reduction at a time of 150 minutes under the same test conditions would theoretically be 10.0 net LOG.
During the test period, the ozone level was consistently below the measurable limits of 0.001 ppm.